RabMAb

Anti-c-Jun (phospho S63)抗体[Y172] (ab32385)

概述

  • 产品名称Anti-c-Jun (phospho S63)抗体[Y172]
    参阅全部 c-Jun 一抗
  • 描述
    兔单克隆抗体[Y172] to c-Jun (phospho S63)
  • 特异性The antibody only detects c-Jun phosphorylated on Serine 63 when tested in WB and ICC using specific phospho-treatments. However, in DotBlot and ELISA assays we detected some cross-reactivity with the non-phospho peptide as well. Please refer to the images on the datasheet.
  • 经测试应用适用于: WB, IHC-P, ICCmore details
    不适用于: Flow Cyt or IP
  • 种属反应性
    与反应: Mouse, Rat, Human
    预测可用于: Cow
  • 免疫原

    A synthetic phospho peptide corresponding to residues surrounding Ser63 of human c-Jun.

  • 阳性对照
    • WB: NIH 3T3 cell lysate. IHC-P: Human breast carcinoma.
  • 常规说明

    This product is a recombinant rabbit monoclonal antibody.

     

    Produced using Abcam’s RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.

    A trial size is available to purchase for this antibody.

性能

应用

Our Abpromise guarantee covers the use of ab32385 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

应用 Ab评论 说明
WB 1/1000 - 1/10000. Detects a band of approximately 42 kDa (predicted molecular weight: 36 kDa).
IHC-P 1/50 - 1/100.
ICC 1/100 - 1/200.
  • 应用说明Is unsuitable for Flow Cyt or IP.
  • 靶标

    • 功能Transcription factor that recognizes and binds to the enhancer heptamer motif 5'-TGA[CG]TCA-3'. Promotes activity of NR5A1 when phosphorylated by HIPK3 leading to increased steroidogenic gene expression upon cAMP signaling pathway stimulation. Involved in activated KRAS-mediated transcriptional activation of USP28 in colorectal cancer (CRC) cells (PubMed:24623306). Binds to the USP28 promoter in colorectal cancer (CRC) cells (PubMed:24623306).
    • 序列相似性Belongs to the bZIP family. Jun subfamily.
      Contains 1 bZIP (basic-leucine zipper) domain.
    • 翻译后修饰Ubiquitinated by the SCF(FBXW7), leading to its degradation. Ubiquitination takes place following phosphorylation, that promotes interaction with FBXW7.
      Phosphorylated by CaMK4 and PRKDC; phosphorylation enhances the transcriptional activity. Phosphorylated by HIPK3. Phosphorylated by DYRK2 at Ser-243; this primes the protein for subsequent phosphorylation by GSK3B at Thr-239. Phosphorylated at Thr-239, Ser-243 and Ser-249 by GSK3B; phosphorylation reduces its ability to bind DNA. Phosphorylated by PAK2 at Thr-2, Thr-8, Thr-89, Thr-93 and Thr-286 thereby promoting JUN-mediated cell proliferation and transformation. Phosphorylated by PLK3 following hypoxia or UV irradiation, leading to increase DNA-binding activity.
      Acetylated at Lys-271 by EP300.
    • 细胞定位Nucleus.
    • Information by UniProt
    • 数据库链接
    • 别名
      • Activator protein 1 antibody
      • AP 1 antibody
      • AP1 antibody
      • cJun antibody
      • Enhancer Binding Protein AP1 antibody
      • Jun Activation Domain Binding Protein antibody
      • JUN antibody
      • Jun oncogene antibody
      • JUN protein antibody
      • Jun proto oncogene antibody
      • JUN_HUMAN antibody
      • JUNC antibody
      • Oncogene JUN antibody
      • p39 antibody
      • Proto oncogene c jun antibody
      • Proto oncogene cJun antibody
      • Proto-oncogene c-jun antibody
      • Transcription Factor AP 1 antibody
      • Transcription factor AP-1 antibody
      • Transcription Factor AP1 antibody
      • V jun avian sarcoma virus 17 oncogene homolog antibody
      • V jun sarcoma virus 17 oncogene homolog (avian) antibody
      • V jun sarcoma virus 17 oncogene homolog antibody
      • V-jun avian sarcoma virus 17 oncogene homolog antibody
      • vJun Avian Sarcoma Virus 17 Oncogene Homolog antibody
      see all

    Anti-c-Jun (phospho S63) antibody [Y172] 图像

    • Lane 1 : Anti-c-Jun (phospho S63) antibody [Y172] (ab32385) at 1/1000 dilution
      Lanes 2 - 3 : Human HRPT2 peptide (ab23385) at 1/1000 dilution

      Lane 1 : HeLa (Human cervix adenocarcinoma epithelial cell) treated with anisomycin. Whole cell lysates with NFDM/TBST
      Lane 2 : HeLa (Human cervix adenocarcinoma epithelial cell) treated with anisomycin. Whole cell lysates with NFDM/TBST
      Lane 3 : HeLa (Human cervix adenocarcinoma epithelial cell) treated with anisomycin. Whole cell lysates15ug. Then the membrane was incubated with phosphatase with NFDM/TBST

      Lysates/proteins at 15 µg per lane.
      Blocking peptides at 5 % per lane.

      Secondary
      Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution (Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated)

      Predicted band size : 36 kDa
    • Cell line A431 (Human epidermoid carcinoma cell line). Target AbID Ab32385 anti-c-Jun (phospho S63) ab150077 AlexaFluor®488 Goat anti-Rabbit secondary. Counterstain AbID Ab195889 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594). Fixative 4% Paraformaldehyde. Permeabilisation 0.1% tritonX-100. Nuclear counter stain DAPI. Datasheet Comments Confocal image showing the expression was increased after treatment with anisomycin (1ug/ml for 15min), then decreased after treatment with the Lambda Protein Phosphatase treatment 31℃ for 2h.

      Target 1oAb dilution

      Target 2ndry Ab dilution

      Counterstain Ab dilution

      1:100

      1 μg/ml

      1:1000

      2 μg/ml

      1:200

      2.5 μg/ml

       

    • Antigen pS63:c-Jun (phospho S63); NP:c-Jun non-phospho. Antigen concentration 0.01~1ng/ml. Primary antibody concentration range 0~1000ng/ml. Secondary antibody Alkaline Phosphatase-conjugated AffiniPure Goat Anti-Rabbit IgG(H+L). Secondary antibody concentration 1:2500 dilution.

    • Primary ab dilution 1:1000 dilution. Secondary ab description and code (ab id)Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051). Secondary ab dilution1:100,000 dilution. Blocking buffer and concentration 5% NFDM/TBST.Diluting buffer and concentration 5% NFDM /TBST. Lane 1:c-Jun (pS63) phospho peptide, Lane 2:c-Jun non-phospho peptide. Exposure time 3 minutes.

    • All lanes : Anti-c-Jun (phospho S63) antibody [Y172] (ab32385) at 1/10000 dilution

      Lane 1 : NIH 3T3 cell lysate not treated with ultraviolet
      Lane 2 : NIH 3T3 cell lysate treated with ultraviolet
      Lane 3 : NIH 3T3 cell lysate not treated with Anisomycin
      Lane 4 : NIH 3T3 cell lysate treated with Anisomycin


      Predicted band size : 36 kDa
      Observed band size : 42 kDa (why is the actual band size different from the predicted?)
      NIH3T3 cells were treated with 25 ug/ml Anisomycin for 15 minutes at 37°C.
    • Ab32385, at a 1/50 dilution, staining c-Jun in paraffin embedded human breast carcinoma tissue by Immunohistochemistry.

    Anti-c-Jun (phospho S63) antibody [Y172] (ab32385)参考文献

    This product has been referenced in:
    • Suwei D  et al. NLK functions to maintain proliferation and stemness of NSCLC and is a target of metformin. J Hematol Oncol 8:120 (2015). Human . Read more (PubMed: 26503334) »
    • Katanov C  et al. Regulation of the inflammatory profile of stromal cells in human breast cancer: prominent roles for TNF-a and the NF-?B pathway. Stem Cell Res Ther 6:87 (2015). WB ; Human . Read more (PubMed: 25928089) »

    See all 11 Publications for this product

    Product Wall

    Application Western blot
    Sample Chicken Cell lysate - whole cell (Chicken thrombocyte)
    Gel Running Conditions Reduced Denaturing (4-20% gradient)
    Loading amount 10 µg
    Specification Chicken thrombocyte
    Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 23°C
    Username

    Mrs. Katie Elliott

    Verified customer

    提交于 Apr 25 2017

    Merci de nous avoir contactés. Nous sommes désolés d'apprendre que le produit que vous avez reçu ne fonctionne pas comme attendu. Je me permets de vous transférer le numéro de commande de remplacement gratuit de ce produit par une unité de ab32385 : ...

    Read More

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"